ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CARA Cara Therapeutics Inc

0.8999
0.0218 (2.48%)
Mar 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 375,848
Bid Price 0.8652
Ask Price 0.88
News -
Day High 0.9297

Low
0.50

52 Week Range

High
5.535

Day Low 0.8006
Company Name Stock Ticker Symbol Market Type
Cara Therapeutics Inc CARA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0218 2.48% 0.8999 19:19:32
Open Price Low Price High Price Close Price Prev Close
0.8713 0.8006 0.9297 0.9074 0.8781
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,030 375,848 $ 0.8445068 $ 317,406 - 0.50 - 5.535
Last Trade Time Type Quantity Stock Price Currency
19:58:55 1 $ 0.879 USD

Cara Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
50.28M 54.66M - 41.87M -85.47M -1.56 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cara Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CARA Message Board. Create One! See More Posts on CARA Message Board See More Message Board Posts

Historical CARA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.98141.010.73490.8693429752,571-0.0815-8.30%
1 Month0.631.150.610.89366331,116,2670.269942.84%
3 Months0.65371.150.500.7472188825,3000.246237.66%
6 Months2.302.310.500.9384994740,822-1.40-60.87%
1 Year5.505.5350.502.33893,220-4.60-83.64%
3 Years19.5029.64730.509.64800,561-18.60-95.39%
5 Years18.3729.64730.5012.45707,598-17.47-95.10%

Cara Therapeutics Description

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Your Recent History

Delayed Upgrade Clock